Most BRCA1 mutation carriers develop triple-negative breast cancers (TNBCs), in which tumors show negative expression of estrogen receptor (ER), progesterone receptor (PR), and Her2 (human epidermal growth factor receptor 2), and these cancers are usually also classified as basal-like breast cancers. This evidence concerns the gene BRCA1 and cancer.